Clinical Trial Update: Accurate Dosimetry and Biomarkers Improve Survival in HCC Patients Treated With Resin 90 Yttrium (90Y)-Microspheres [Phase 2]

View source ↗

Summary

A Phase 2 trial exploring accurate dosimetry and biomarkers for patients with hepatocellular carcinoma treated with resin 90Y microspheres to improve survival.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• resin 90Y microspheres (Yttrium-90 resin microspheres)

Snippet

Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna | Conditions: HCC | Phase 2 | Status: UNKNOWN